SKB BIO (06990.HK) plans to issue in total 5.84 million shares by placement, with estimated net proceeds of HKD 2.72 billion
NewTimeSpace (newtimespace.com) News, SKB BIO (06990.HK) announced on Jul 8, 2026 that the company has entered into a placement agreement with the placement agent on Jul 8, 2026. According to the agreement, the placing agent conditionally agreed to use its best endeavors to procure placees to subscribe for in total 5.84 million shares placement, which represent approximately 2.5% of the company's existing issued share capital as of the date of this announcement, and approximately 2.44% after the subscription.
The placement price per share is HKD 470.2. The total proceeds from the placement are estimated to be about HKD 2.75 billion. After deducting the placement commission, professional fees, and all related expenses that the company may incur, the net proceeds from the placement are estimated to be approximately HKD 2.72 billion.NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- SKB BIO (06990.HK): Positive Phase II Interim Results for SKB378/WIN378 in Asthma; Phase III Initiated
- SKB BIO(06990.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 388.01 million, turned profitable from a loss YoY
- SKB BIO (06990.HK): NMPA Accepts sNDA for Core Product Sac-TMT in First-Line TNBC Treatment
- YANCOAL AUS (03668.HK): Completes Acquisition of 80% Interest in Kestrel
- HAIWEI ELEC (09609.HK): Southern China Plant to Make Ultra-Thin Films